Jubilant bags $92-m deal

New Delhi: Jubilant Organosys Ltd has got new contracts worth $92 million under its custom research and manufacturing services business for the calendar year 2008.

Given Jubilant’s geographical focus on the regulated markets, a large percentage of these contracts are realisable from the US, Europe and Japan. Outside the geographical region of the regulated markets, China is a major market for Jubilant.

“Jubilant’s order book for the calendar year stands further augmented with the addition of these contracts –the increase in size, over a similar announcement made last year, is over 50 per cent. The new contracts have been signed with major international pharma and other life sciences companies,” said a company statement.

Product pipeline

The company said it had a healthy pipeline of products which are in Phase III (stage of development at the customers end); and to support this it has made timely investments to expand key capacities.

These contracts represent a huge opportunity for volume growth going forward for the exclusive synthesis and contract manufacturing segments under CRAMS.

Mr Shyam S. Bhartia, Chairman and Managing Director, Jubilant Organosys, said: “The signing of the recent agreements is expected to translate into considerable improved performance in the key pharma and life sciences products segment during calendar 2008.”